Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from May 28, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 26, 2026 — +6% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$42.41 – $44.36Entry zone — fair-value band

$44.52Published — price the day we called it

$47.04Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$47.19Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 29 days.

At window close

+6%

realized, from the publication price to the last close inside the window

Peak gain

+15.6%

peak, from the publication price — not a realized return

S&P 500, same window

+1.8%

SPY over the identical days, dividend-adjusted

Window close

$47.19

last close inside the window, ended August 26, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

The thesis — published May 28, 2026

Predicted growth

+7%

over the measurement window

Target price

$47.04

the price the thesis aimed for

Entry zone

$42.41 – $44.36

the fair-value band we waited for

Price at publication

$44.52

published May 28, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is a steady-growth healthcare stock tied to strong demand for diabetes and obesity treatments. Recent news shows both rising demand and pressure on prices, especially where patients pay cash. That mix limits near-term upside and creates cautious momentum, yet the core business looks appealing near current support over the next 0-3 months as rivals increase competition.

Primary drivers

Leading in GLP-1 drugs supports steady demand
Big diabetes business offers defensive healthcare exposure
Price headlines add access risk and expand the market
Lower price swings help balance a growth portfolio

How it played out

NVO: target reached in 29 days

Lyra published a cautious short-term thesis at 44.52, expecting 7% growth over 0-3 months. The thesis pointed to steady demand for diabetes and obesity treatments, a large diabetes business, pricing and access risks, and lower price swings. It also noted rising competition and limited near-term upside.

The shares reached 47.04 in 29 days. They later peaked at 51.46 on July 29, 2026, a 15.6% gain. The window ended with the price at 47.19, still above the target. The thesis played out fully within the measurement window.

What happened during the window

On June 7, 2026, Novo Nordisk reported that Wegovy pill prescriptions had passed 3 million. On August 4, 2026, the company reported 7% adjusted sales growth and 11% adjusted operating profit growth for Q2 2026 at constant exchange rates, and raised its full-year outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals